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INHIBITORS ON ADVERSE CARDIOVASCULAR OUTCOMES IN COMMERCIALLY
INSURED PATIENTS WITH ACUTE CORONARY SYNDROME
Bhurke S, Martin B, Li C, Franks A, Bursac Z, Said Q
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: Following a FDA warning in November 2009, significant controversy
exists regarding the outcomes of patients co-medicated with clopidogrel and
omeprazole after acute coronary syndrome (ACS). This study examined the effect
of proton pump inhibitors (PPI) –clopidogrel interactions on subsequent ACS emer-
gency department and inpatient visits.METHODS: This was a retrospective cohort
study of administrative claims data for a large nationally dispersed group of com-
mercially insured subjects between 2001 and 2008. Subjects age 18 years with a
diagnosis of ACS and at least one clopidogrel prescription within 90 days after the
diagnosis were included. The clopidogrel plus PPI (CPPI) group was defined as
subjects with a minimum of 7 days overlap between the PPI and clopidogrel pre-
scriptions. Subjects were followed from their first clopidogrel prescription until
they experienced a re-hospitalization or ER visit due to ACS, disenrolled or reached
the study end. CPPI group was matched 1:1 with clopidogrel group using propen-
sity scoring methods with calipers. Cox proportional hazards regression was used
to estimate the relative risk of an adverse cardiovascular event. RESULTS: Of the
10,101 patients taking clopidogrel, 16.98% (n1,716) were prescribed a PPI. Propen-
sity matching resulted in 1,697 patient pairs. The mean age was 61.50 years with a
mean follow up of 259 days and 69.64% were males. 13.20% (n224) had an ACS-
related re-hospitalization or ER visit in the clopidogrel group versus 16.32% (n277)
in the CPPI group. CPPI usewas not associatedwith a significantly increased risk
of adverse outcomes (HR1.221; 95% CI, 0.984-1.517) compared to clopidogrel users
not co-medicated with a PPI. CONCLUSIONS: Concurrent use of clopidogrel and
PPIs trended toward a non-significant increase in risk of adverse cardiovascular
outcomes for ACS patients, which suggests caution may be warranted when pre-
scribing a PPI with clopidogrel. Future studies should account for time dependence
of exposure.
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PNEUMONIA AFTER ACUTE ISCHEMIC STROKE: PREVALENCE, ASSOCIATED
FACTORS AND OUTCOMES
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OBJECTIVES: Pneumonia is one of the most frequent medical complications of
acute ischemic stroke, often apparent early after stroke onset, and it is associated
with increased risk of death after stroke attack. We aimed to identify clinically
useful factors associatedwith pneumonia, and to examine the effect of pneumonia
on patient’s functional outcome at discharge and on in-hospital mortality after the
attack. METHODS: It is an evaluation of post-stroke pneumonia complication
among ischemic stroke patients attending a hospital inMalaysia fromNovember 1,
2008 to April 30, 2009. Data included demographic information, risk factors and
clinical characteristics. Functional outcome at discharge as measured by the Mod-
ified Barther Index (MBI) and in-hospital mortality were assessed. Poor outcome
was defined as MBI  75. SPSS version 15 was used for data analysis. RESULTS: A
total of 256 patients were studied, of which 33 (12.9%) experienced pneumonia
complication during hospitalization. The key baseline factors associated with the
occurrence of post-stroke pneumonia were total anterior circulation infarct (P 
0.001), moderate and severe Glasgow Coma Scale (P  0.001), atrial fibrillation (P 
0.035) and renal impairment (P  0.001). Moreover, 24 (60%) of dead cases were
suffering from pneumonia during hospitalization (P  0.001). Additionally, after
excluding the dead cases, 8 (9.2%) of patients discharged with poor functional
outcome were having pneumonia during their hospital stay (P  0.002).
CONCLUSIONS: Pneumonia is independently associatedwith ischemic stroke poor
outcome. Identification of medical history and clinical characteristics on admis-
sion can assist clinicians to identify patients at higher risk of developing post-
stroke pneumonia thus hastening the initiation of certain interventions to improve
patient outcome.
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HEALTH CARE
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OBJECTIVES: To examine the impact of potential DDIs on health outcomes and the
associated cost to the Mississippi Medicaid program. METHODS: A retrospective
matched cohort study was conducted in Mississippi Medicaid enrollees for years
2002-2004. Enrollees were classified as exposed to a potential DDI if the object and
precipitant drugswere possessed concomitantly, with first day of overlap being the
DDI event date. Exposed enrollees were matched to enrollees taking object drugs
without a potential DDI based on demographic, comorbidity and object drug-re-
lated variables. Controls were assigned the event date for the matched exposed
case. Conditional logistic regression was used to analyze the effect on health out-
comes (hospitalizations and ER visits within 30 days of potential DDI) and paired
t-tests for costs to Mississippi Medicaid. RESULTS: DDIs with the greatest health
and economic effects included: ACE/ARBs –– odds ratio (OR) for hospitalizations 
1.75, OR for ER visits  1.39, difference in average per patient hospital payments
(	APPHP)  $124, and difference in average per patient ER payments (	APPERP) 
$63); beta blockers –– OR for hospitalizations  1.52, OR for ER visits  1.24 (n.s.),
	APPHP  $78.13, and 	APPERP  $43.67; clonidine –– OR for hospitalizations 
1.67, OR for ER visits  1.35, 	APPHP  $50, 	APPHP  $8.17; warfarin with quino-
lone ––OR for hospitalizations 1.17 (n.s.), OR for ER visits 1.27;	APPHP $83.35,
and 	APPERP $48.14); warfarin with thyroid hormones –– OR for hospitalizations
 2.47, OR for ER visits  1.96, 	APPHP  $106.03, and 	APPERP  $100.33.
CONCLUSIONS: Based on these findings, Medicaid intervention strategies to re-
duce the incidence of potential DDIs should be a cost-effectivemethod for improv-
ing health care quality and thus a priority for state Medicaid programs.
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OBJECTIVES: Atrial fibrillation (AF) may manifest with comorbidities. We exam-
ined the prevalence of comorbidities and general medication use among AF pa-
tients in order to assess total disease burdenMETHODS: Data were obtained from
the 2009 National Health and Wellness Survey (N75,000), an annual cross-sec-
tional Internet-based survey of adults in the United States. In addition to demo-
graphics and medication use, patients with AF also reported on their comorbid
conditions. Using demographic and patient characteristics, a CHADS2 score (an
index of stroke risk) was calculated for each patient. RESULTS: A total of 1297
patients reported a diagnosis of AF. Themean agewas 64.9 years (SD 12.2), and 65%
were male. In addition to AF, these patients reported comorbidities in various
organ systems, including 90% with a cardiovascular condition, 62% with a urolog-
ical condition, 42% with a respiratory condition, and 41% with a gastrointestinal
condition. Specific comorbid conditions reported in this AF patient population in-
cluded hypertension in 72% of patients, history of myocardial infarction in 21% of
patients, heartburn/gastroesophageal reflux disease in 29% of patients, and aller-
gies/hay fever in 29% of patients. Themean Charlson Comorbidity Index score was
1.53 for all patients. Almost half of patients (46%) had a CHADS2 score of 2. The
percentage of patients reporting current medication use included: 71% for AF, 64%
for hypertension, 50% for hyperlipidemia, 29% for arrhythmia, 24% for diabetes,
and 26% for gastrointestinal medications. Overall, 43% of patients with AF were
using an anticoagulant medication. CONCLUSIONS: This self-reported national
survey identified AF patients as having a high comorbidity burden, with conditions
affecting a variety of organ systems. Medications used to treat a variety of condi-
tions are also highly prevalent and should be taken into account in managing
patients with AF.
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OBJECTIVES: Many agents used in treating AF have potential gastrointestinal (GI)
tolerability issues. Treatment-related adverse GI events are a common reason for
noncompliance to treatment. The current analysis describes the prevalence of
dyspepsia in relation to anticoagulant use among AF patients. METHODS: Data
were obtained from the 2009 National Health and Wellness Survey (N75,000), an
annual cross-sectional Internet-based survey of US adults. Respondents answered
general demographic and health-related questions. A CHADS2 score (an index of
stroke risk) was calculated for each patient using demographic and clinical
characteristics. RESULTS: A total of 1297 patients (1.7%) reported a diagnosis of AF.
Of these patients, 535 (41%) also reported a physician-diagnosed GI condition; 449
of these (84%) were consistent with dyspepsia (ulcers, abdominal bloating, abdom-
inal pain, gastroesophageal reflux disease/acid reflux, or heartburn). Compared
with AF patients without dyspepsia (n848), those with dyspepsia were younger
(mean 62.9 vs. 66.0 years, p0.05) and more likely to be female (43% vs. 31%,
p0.05). AF patients with dyspepsia were in poorer health than those without
dyspepsia, as evidenced by a higher CHADS2 score (1.9 vs. 1.4, p0.05); this differ-
ence was more pronounced in patients aged 65 years and in those with CHADS2
score2. Despite this, significantly fewer AF patients with than without dyspepsia
were taking a prescription medication to treat AF (67% vs. 73%, p0.05) or an anti-
coagulant for stroke prevention (35% vs. 47%, p0.05). CONCLUSIONS:One-third of
AF patients in this analysis had dyspepsia. These patients reported a greater dis-
ease burden and stroke risk relative to AF patients without dyspepsia. Significantly
fewer AF patients with than those without dyspepsia were taking a prescription to
treat AF or an anticoagulant for stroke prevention. Poor GI tolerability may be
significant in the AF population and should be considered when adherence to
medication is critical, such as in high-risk populations.
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PREDICTORS OF THE COMBINED DIAGNOSIS HYPERLIPIDEMIA AND
HYPERTENSION - A NHANES 2007-2008 STUDY
Bhounsule P, Abughosh S
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OBJECTIVES: Cardiovascular disease (CVD) remains the leading cause of death in
the United State (US). Both hyperlipidemia and hypertension are known risk fac-
tors for CVD. Tobacco use augments this risk by lowering the HDL cholesterol,
increasing blood clotting, and acutely elevating blood pressure. The objective of
this study was to examine predictors of having both co-morbidities including de-
mographic characteristics and smoking status METHODS: A retrospective cross-
sectional study was conducted using the NHANES 2007-2008 database, a stratified
multistage probability sample of the civilian non-institutionalized US population.
The outcome variable was defined as being diagnosed with both hypertension and
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